The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Add Type 1 Diabetes to Opdivo Label: MHLW
November 26, 2015
- Exemption of Clinical Trials in Japanese Subjects Depends on Factors Such as Possibility to Infer Safety: PMDA
November 26, 2015
- Chuikyo Agrees on Setting Range, Not Fixed Threshold, to Judge Cost Effectiveness of Drugs
November 25, 2015
- Don’t Seek Near-Term Profits but Have Long-Term Vision, MHLW Official Tells Drug Makers
November 25, 2015
- MOF Panel Submits Budget Recommendation, Calls for Wrapping Up Talks on Frequency of Drug Price Revisions by Mid-2018
November 25, 2015
- AMED to Allocate 150 Million Yen to Development of In Vitro Diagnostics for Breast and Colorectal Cancer
November 25, 2015
- Generic Prices Should Be Below 50% of Original Drug Prices: Govt Panel Members
November 25, 2015
- MHLW Eyes Using HTA to Re-Price Drugs with Big Sales Outlooks That Have Gone Through 1 or 2 Price Revisions
November 24, 2015
- MHLW OKs Add’l Indications for Lexapro, Other Drugs
November 24, 2015
- Bristol’s MM Drug Elotuzumab Gets Orphan Status
November 24, 2015
- Chuikyo Advisor Submits Guidelines for Cost-Effective Assessments that Would Include Measures Other than QALY
November 24, 2015
- AMED Looks to Bridge “Valley of Death” with Pre-Orphan Designation Scheme
November 20, 2015
- Pharmas Present 9 Requests on Drug Pricing, Tax to LDP Study Group
November 20, 2015
- MHLW Panel Approves Additional Shipment of Kaketsuken’s Venilon, Novact
November 20, 2015
- Viekirax Price, Peak Sales Forecast Called into Question
November 19, 2015
- Chuikyo OKs Viekirax, Other Drugs for NHI Price Listing on Nov. 26
November 19, 2015
- Chuikyo Approves Listing of Temcell and HeartSheet, First Two Regenerative Medicine Products
November 19, 2015
- AbbVie’s Hep C Drug Viekirax Priced at 53,000 Yen Daily vs. Harvoni’s 80,000 Yen
November 18, 2015
- MHLW Cautions against Reference Pricing, Says Impact on Pharmas Would Be Huge
November 18, 2015
- Research-Driven Drug Makers Should Collaborate with Startups, Academia: MHLW Official
November 17, 2015
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…